Press release
HER2-Positive Breast Cancer Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight
HER2-Positive Breast Cancer Clinical Trials
Key Takeaways from the HER2-Positive Breast Cancer Pipeline Report
• DelveInsight's HER2-Positive Breast Cancer pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for HER2-Positive Breast Cancer treatment.
• The leading companies working in the HER2-Positive Breast Cancer Market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
• Promising HER2-Positive Breast Cancer Pipeline Therapies in the various stages of development include TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.
• April 2024:- Seagen Inc.- A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05).
• April 2024: Alliance for Clinical Trials in Oncology- The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib.
• March 2024: Dana-Farber Cancer Institute- Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer.
• March 2024: Daiichi Sankyo- EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan Through a Named Patient Program (EUROPA T-DXd).
Request a sample and discover the recent advances in HER2-Positive Breast Cancer Treatment Drugs @ HER2-Positive Breast Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the HER2-Positive Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
HER2-Positive Breast Cancer Overview
Breast cancer is not a single disease but a group of diseases. Scientists discovered human epidermal growth factor receptor 2 (HER2)-positive breast cancer when searching for genes that cause cancer. On the most basic level, cancer is the result of normal cells growing unchecked, an observation that led researchers to speculate that specific genes or gene mutations enable this to occur.
Find out more about HER2-Positive Breast Cancer Therapeutics Assessment @ HER2-Positive Breast Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
HER2-Positive Breast Cancer Emerging Drugs Profile
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• HLX11: Shanghai Henlius Biotech
• MCLA-128: Merus N.V.
• DX126 262: Hangzhou DAC Biotech
HER2-Positive Breast Cancer Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for HER2 Positive Breast Cancer. The HER2-Positive Breast Cancer companies which have their HER2 Positive Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.
DelveInsight's HER2-Positive Breast Cancer pipeline report covers around 65+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
HER2-Positive Breast Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging HER2-Positive Breast Cancer Pipeline Therapies @ HER2-Positive Breast Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the HER2-Positive Breast Cancer Pipeline Report
• Coverage- Global
• HER2-Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HER2-Positive Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
• HER2-Positive Breast Cancer Pipeline Therapies- TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.
Dive deep into rich insights for new drugs for HER2-Positive Breast Cancer Treatment, Visit @ HER2-Positive Breast Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. HER2 Positive Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Positive Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. MCLA-128: Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DX126 262: Hangzhou DAC Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ES2B C001: ExpreS2ion Biotechnologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Positive Breast Cancer Key Companies
21. HER2 Positive Breast Cancer Key Products
22. HER2 Positive Breast Cancer- Unmet Needs
23. HER2 Positive Breast Cancer- Market Drivers and Barriers
24. HER2 Positive Breast Cancer- Future Perspectives and Conclusion
25. HER2 Positive Breast Cancer Analyst Views
26. HER2 Positive Breast Cancer Key Companies
27. Appendix
For further information on the HER2-Positive Breast Cancer Pipeline therapeutics, reach out to HER2-Positive Breast Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2-Positive Breast Cancer Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight here
News-ID: 3564488 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
